Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Royal Challengers Bengaluru stay alive with win over Gujarat Titans in IPLAlcaraz earns another comfortable win in Madrid. Spaniard is making successful return from injuryExperts caution against underestimating 'indolent tumors'Erick Fedde stars as White Sox sweep Rays with 4Celtics coach Joe Mazzulla says playoff basketball doesn't change much from regular seasonGausman pitches 7 innings for first win as Blue Jays cool off Dodgers with 3Bayern and Dortmund seek Champions League glory to kick off big summer of soccer for GermanyNurse hat trick helps Toronto clinch topSenzel homers twice, Nationals erase 7Strictly Come Dancing star 'set to join Celebrity Gogglebox with his younger brother and dad'